PMID- 22339220
OWN - NLM
STAT- MEDLINE
DCOM- 20121218
LR  - 20220311
IS  - 1873-4316 (Electronic)
IS  - 1389-2010 (Linking)
VI  - 13
IP  - 8
DP  - 2012 Jun
TI  - Monoclonal antibodies for the immunotherapy of solid tumours.
PG  - 1385-98
AB  - More than 80% of all cancers are caused by solid malignancies. More than 90% of 
      these tumours are of epithelial origin. The main principles in tumour treatment 
      are surgery, radiotherapy, chemotherapy or combinations of these. Complete 
      surgical removal of the tumour is the most effective therapy for solid 
      malignancies. Recent advances in early cancer detection led to a higher rate of 
      resectable primary tumours and therefore prognosis will be determined especially 
      by metastasis. Even in early stages some tumour cells may disseminate for example 
      into the bone marrow. If these occult metastasis get evident they are mostly 
      incurable by surgery and often highly resistant to chemotherapy. Developing new 
      therapeutic agents to destroy these resting cells is a major challenge for the 
      improvement of cancer therapy in the future. Advances to reach these goals were 
      made in immunological therapies with monoclonal antibodies (MABs). These MABs are 
      for example directed against tumor-associated antigens (TAAs). By binding 
      selectively on tumor cells they can activate immunological effector mechanisms, 
      e.g. antibody dependent cell cytotoxicity (ADCC) or complement mediated lysis. 
      Other mechanisms are the blocking of inhibiting molecules to re-activate anergic 
      tumor infiltrating lymphocytes (TILs). Furthermore growing tumours depend on 
      oxygen supply, i.e. on effective neovascularisation. Antibodies against VEGF are 
      able to inhibit neovascularisation and are therefore used successfully in tumour 
      therapy.
FAU - Mauerer, Richard
AU  - Mauerer R
AD  - synlab MVZ Labor Munchen Zentrum GbR, Bayerstrasse 53, 80335 Munchen, Germany.
FAU - Gruber, Rudolf
AU  - Gruber R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Humans
MH  - *Immunotherapy
MH  - Neoplasms/immunology/*therapy
EDAT- 2012/02/22 06:00
MHDA- 2012/12/19 06:00
CRDT- 2012/02/21 06:00
PHST- 2010/05/14 00:00 [received]
PHST- 2010/08/27 00:00 [revised]
PHST- 2010/09/03 00:00 [accepted]
PHST- 2012/02/21 06:00 [entrez]
PHST- 2012/02/22 06:00 [pubmed]
PHST- 2012/12/19 06:00 [medline]
AID - CPB-EPUB-20120214-006 [pii]
AID - 10.2174/138920112800784844 [doi]
PST - ppublish
SO  - Curr Pharm Biotechnol. 2012 Jun;13(8):1385-98. doi: 10.2174/138920112800784844.